Established Cardiovascular Disease Treatment Algorithm by Line of Therapy

Who Qualifies as Having Established Cardiovascular Disease

Established cardiovascular disease (CVD) is defined by objective evidence of atherosclerotic injury or its clinical sequelae. Patients in this category carry the highest absolute risk of recurrent major adverse cardiovascular events (MACE), which is why secondary prevention targets are uniformly more aggressive than primary prevention thresholds.

Diagnostic Criteria

The ACC/AHA 2022 Guideline on Chest Pain and the 2019 ACC/AHA Guideline on Primary Prevention define established CVD as any of the following: prior myocardial infarction (MI), ischemic stroke or TIA, peripheral arterial disease (ABI <0.90), prior coronary or peripheral revascularization, or documented obstructive CAD on imaging (stenosis >50% in a major epicardial artery) [1, 2].

Symptomatic stable coronary disease also qualifies. Asymptomatic individuals with subclinical atherosclerosis (coronary artery calcium score >100 Agatston units) are considered high risk but do not yet meet the established CVD threshold for the most aggressive secondary prevention drug intensification.

Risk Stratification Within the Established CVD Population

Not all patients with established CVD carry identical residual risk. The 2021 ESC Guidelines on Cardiovascular Disease Prevention classify patients with polyvascular disease, recent ACS (<1 year), or diabetes plus target organ damage as "very high risk," warranting LDL-C targets below 55 mg/dL and dual-pathway therapy [3].

The TIMI Risk Score for secondary prevention and the SMART risk score can further stratify 10-year recurrent MACE probability from approximately 10% to over 30%, guiding the intensity of add-on therapies discussed below.

First-Line Therapy: The Four-Drug Foundation

Every adult with established CVD should, barring contraindication, be on all four first-line agents simultaneously. These are not sequential choices. They address distinct biological pathways and their benefits are additive.

High-Intensity Statin Therapy

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol recommends high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for all patients with established ASCVD regardless of baseline LDL-C [4]. The Cholesterol Treatment Trialists' Collaboration meta-analysis (n=170,000 across 26 trials) showed each 1 mmol/L (39 mg/dL) reduction in LDL-C reduces MACE by approximately 22% (RR 0.78, 95% CI 0.76 to 0.80) [5].

Target LDL-C is <70 mg/dL per ACC/AHA 2022 and <55 mg/dL per 2019 ESC/EAS guidelines [4, 6]. Patients already on high-intensity statin therapy who remain above these targets should move directly to second-line LDL-lowering agents rather than waiting.

Antiplatelet Therapy

Aspirin 75 to 100 mg/day reduces recurrent MI by approximately 25% in patients with established ASCVD per the Antithrombotic Trialists' Collaboration analysis of 195 trials (n=135,000) [7]. Following ACS, the ACC/AHA 2022 Chest Pain Guideline recommends dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for at least 12 months [1].

Clopidogrel 75 mg/day is an acceptable alternative for patients intolerant of aspirin, based on the CAPRIE trial (N=19,185), which showed a statistically significant 8.7% relative risk reduction in MACE vs. Aspirin alone [8].

ACE Inhibitors and ARBs

The HOPE trial (N=9,297) demonstrated that ramipril 10 mg/day reduced the composite of MI, stroke, or CV death by 22% (RR 0.78, P<0.001) in high-risk patients with established vascular disease [9]. Perindopril, lisinopril, and enalapril carry similar secondary prevention evidence.

For patients who develop ACE inhibitor cough, an ARB (losartan, valsartan, or telmisartan) is substituted. The ONTARGET trial (N=25,620) confirmed that telmisartan was non-inferior to ramipril for the primary MACE composite [10]. The 2022 ACC/AHA Guideline on Heart Failure recommends ACE inhibitors or ARBs in all patients with reduced ejection fraction, with the additional benefit of sacubitril/valsartan in HFrEF <35% [11].

Beta-Blockers Post-MI

Beta-blockers reduce post-MI mortality. The 2022 ACC/AHA Guideline on Management of Patients with Chronic Coronary Disease recommends beta-blocker therapy for at least 1 to 3 years after MI with reduced LVEF, and indefinitely in patients with ongoing angina or heart failure [12]. Carvedilol, metoprolol succinate, and bisoprolol have the strongest mortality evidence in the HFrEF population from trials including CARVEDILOL (N=1,094) and MERIT-HF (N=3,991) [13, 14].

Beta-blocker use in patients with preserved EF beyond the first year post-MI is debated, with observational data from the KAMIR-NIH registry (N=13,104) suggesting no mortality benefit beyond 2 years in EF >50% patients [15].

Second-Line Therapy: Residual LDL-C and Glucose Risk

When first-line therapy fails to achieve LDL-C or glycemic targets, second-line agents address residual risk through complementary mechanisms.

Ezetimibe

Ezetimibe 10 mg/day added to statin therapy inhibits intestinal cholesterol absorption and lowers LDL-C by an additional 18 to 24% [4]. The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe to simvastatin after ACS reduced the composite MACE endpoint by 6.4% relative (HR 0.936, P=0.016) over 7 years, with the greatest benefit in patients with diabetes [16].

Ezetimibe is generic, well-tolerated, and should precede PCSK9 inhibitors in the intensification sequence for cost reasons unless LDL-C remains >40 mg/dL above target after statin plus ezetimibe.

PCSK9 Inhibitors

For patients who remain above LDL-C targets on maximally tolerated statin plus ezetimibe, PCSK9 inhibitors (evolocumab 140 mg Q2W or alirocumab 75 to 150 mg Q2 to 4W) are the next step. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% and cut the key secondary MACE endpoint by 15% (HR 0.85, P<0.001) compared to placebo on background statin therapy [17]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced MACE by 15% (HR 0.85, P<0.001) in post-ACS patients [18].

Inclisiran 284 mg Q6 months (after initial doses at day 0 and day 90) is an siRNA-based PCSK9 inhibitor approved by the FDA in December 2021 [19]. The ORION-10 trial (N=1,561) showed inclisiran reduced LDL-C by 52% at day 510 vs. Placebo (P<0.001); cardiovascular outcomes data from ORION-4 are expected in 2025 [20].

SGLT2 Inhibitors

SGLT2 inhibitors now have a defined role in secondary CVD prevention independent of their glucose-lowering effect. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin 10 to 25 mg reduced the composite of CV death or hospitalization for heart failure (HHF) by 34% (HR 0.66, P<0.001) and CV death alone by 38% [21]. The DAPA-HF trial (N=4,744) showed dapagliflozin reduced worsening HF or CV death by 26% (HR 0.74, P<0.001) in patients with HFrEF regardless of diabetes status [22].

The 2024 ADA Standards of Care recommend empagliflozin or dapagliflozin for patients with established CVD and type 2 diabetes, and for all patients with HFrEF regardless of diabetes status [23].

Third-Line Therapy: GLP-1 Receptor Agonists and Advanced Lipid Lowering

GLP-1 Receptor Agonists in Established CVD

GLP-1 receptor agonists have moved from diabetes-specific drugs to agents with a primary cardiovascular indication. The SELECT trial (N=17,604) is the most important development in this space: semaglutide 2.4 mg subcutaneously once weekly reduced the primary composite of CV death, non-fatal MI, and non-fatal stroke by 20% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) in adults with overweight or obesity and established CVD who did not have diabetes [24]. This was the first MACE trial to demonstrate benefit from a GLP-1 receptor agonist in a non-diabetic population.

Earlier CVOT data reinforced the class benefit in diabetic patients with established CVD. The LEADER trial (N=9,340) showed liraglutide 1.8 mg reduced 3-point MACE by 13% (HR 0.87, P=0.01) [25]. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 to 1 mg reduced 3-point MACE by 26% (HR 0.74, P<0.001 for non-inferiority, P=0.02 for superiority) [26].

The 2024 ADA Standards of Care recommend a GLP-1 receptor agonist with proven CVOT benefit for patients with type 2 diabetes and established CVD regardless of HbA1c, and note that semaglutide 2.4 mg (Wegovy) may be used for secondary MACE prevention in patients with established CVD and BMI >27 kg/m² without diabetes [23].

Selecting the Right GLP-1 Agent

Not all GLP-1 receptor agonists carry the same cardiovascular evidence. Dulaglutide demonstrated MACE benefit in REWIND (N=9,901; HR 0.88, P=0.026) [27], making it an option when weekly injection is preferred and cost matters. Albiglutide showed benefit in HARMONY Outcomes (N=9,463; HR 0.78, P=0.0006) [28] but was withdrawn from the US market for commercial reasons in 2020.

Exenatide (EXSCEL, N=14,752) showed non-inferior but not superior MACE outcomes (HR 0.91, P=0.06 for superiority) [29]. The 2023 AACE/ACE Comprehensive Diabetes Management Algorithm specifically lists liraglutide, semaglutide, and dulaglutide as preferred agents in patients with established ASCVD, designating exenatide as an alternative [30].

Bempedoic Acid

Bempedoic acid 180 mg/day is an oral, non-statin LDL-lowering agent that inhibits ATP-citrate lyase upstream of HMG-CoA reductase. The CLEAR Outcomes trial (N=13,970) enrolled statin-intolerant patients and demonstrated a 13% reduction in the primary 4-point MACE composite (HR 0.87, P=0.004) with bempedoic acid vs. Placebo over a median follow-up of 40.6 months [31]. LDL-C was reduced by 21.1% from baseline.

Bempedoic acid does not cause myopathy because it requires hepatic activation via an enzyme (ACSVL1) absent in skeletal muscle, making it suitable for patients who cannot tolerate any statin dose [31].

Fourth-Line and Emerging Therapies

Icosapent Ethyl (IPE)

REDUCE-IT (N=8,179) showed that icosapent ethyl (Vascepa) 4 g/day reduced the primary 5-point MACE endpoint by 25% (HR 0.75, P<0.001) in patients with established CVD or diabetes plus additional risk factors and triglycerides 135 to 499 mg/dL on statin therapy [32]. CV death was reduced by 20% (HR 0.80, P=0.03). The FDA approved icosapent ethyl for this indication in December 2019 [33].

The mechanism likely extends beyond triglyceride reduction. JELIS (N=18,645) showed EPA supplementation reduced MACE by 19% in Japanese patients, though at a lower dose (1.8 g/day) and without the mineral oil placebo controversy that surrounded REDUCE-IT [34].

Colchicine

The inflammatory hypothesis of atherosclerosis has direct drug support. COLCOT (N=4,745) showed colchicine 0.5 mg/day started within 30 days of MI reduced the primary composite MACE endpoint by 23% (HR 0.77, P=0.02) [35]. The LoDoCo2 trial (N=5,522) extended this finding to stable chronic coronary disease, showing a 31% reduction in MACE (HR 0.69, P<0.001) [36].

The ACC/AHA 2023 Guideline on Chronic Coronary Disease gives colchicine a Class IIb recommendation (may be reasonable) for selected high-risk patients with recurrent events on optimal medical therapy [12]. The key adverse effect to monitor is gastrointestinal intolerance (approximately 9 to 13% of patients in trials) and rare drug interactions with CYP3A4 inhibitors.

Rivaroxaban Low-Dose

COMPASS (N=27,395) showed rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day reduced MACE by 24% (HR 0.76, P<0.001) compared to aspirin alone in patients with stable CAD or PAD, at the cost of increased major bleeding (HR 1.70, P<0.001) [37]. The FDA approved this combination for secondary prevention of MACE in adults with stable CAD or PAD in October 2018 [38]. Patient selection (lower bleeding risk, high ischemic risk, polyvascular disease) is important before initiating.

Lifestyle Therapy Across All Lines

Drug therapy does not replace lifestyle modification. The PREDIMED trial (N=7,447) showed a Mediterranean diet supplemented with olive oil or nuts reduced MACE by 30% compared to a low-fat control diet in high-risk patients (HR 0.70, P=0.001) [39]. All four major society guidelines (ACC/AHA 2022, ESC 2021, ADA 2024, AACE 2020) [1, 3, 23, 30] recommend:

• Dietary sodium <2,300 mg/day
• Saturated fat <7% of total calories
• At least 150 minutes of moderate-intensity aerobic exercise per week
• Smoking cessation (varenicline reduces CV events by approximately 34% in high-risk patients per the EAGLES trial, N=8,144) [40]
• Body weight reduction of 5 to 10% where BMI >27 kg/m²

Cardiac rehabilitation after MI or revascularization reduces all-cause mortality by approximately 20% (OR 0.80, 95% CI 0.68 to 0.93) per a 2016 Cochrane review of 63 trials (N=14,486) [41].

Blood Pressure Targets in Established CVD

The 2017 ACC/AHA Hypertension Guideline lowered the BP target for high-risk patients, including those with established CVD, to <130/80 mmHg [42]. The SPRINT trial (N=9,361) showed intensive systolic BP treatment targeting <120 mmHg reduced the primary composite MACE endpoint by 25% (HR 0.75, P<0.001) in high-risk non-diabetic patients, though it excluded prior stroke and diabetes [43].

ACE inhibitors, ARBs, and long-acting dihydropyridine calcium channel blockers (amlodipine) are preferred antihypertensive agents in established CVD based on outcomes data [42]. Thiazide diuretics (chlorthalidone 12.5 to 25 mg/day) add significant BP-lowering in resistant hypertension and were the backbone agent in ALLHAT (N=42,418), which showed chlorthalidone non-inferior to amlodipine or lisinopril for prevention of fatal CHD and non-fatal MI [44].

Glycemic Management in Established CVD with Diabetes

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce cardiovascular events, independent of HbA1c" [23]. This moves these agents from glucose-control adjuncts to primary cardiovascular therapy.

HbA1c targets in this population are generally 7.0 to 8.0% per ADA 2024, with less aggressive targets (<8.0 to 8.5%) in patients with long disease duration, significant hypoglycemia risk, or advanced comorbidities [23]. Metformin remains first-line for glucose lowering given its safety profile and the UKPDS 34 data showing a 39% reduction in MI (P=0.01, N=753) in overweight patients with newly diagnosed T2DM [45].

Putting the Algorithm Together: A Practical Summary

The treatment sequence for a patient with established CVD follows a clear logic. Start all eligible patients on the four-drug foundation at diagnosis or at first contact. Reassess LDL-C at 4 to 6 weeks. Add ezetimibe if LDL-C remains above target. Add a PCSK9 inhibitor if LDL-C remains above 55 to 70 mg/dL despite statin plus ezetimibe.

Assess for HF with echocardiography. Add SGLT2 inhibitor if EF <35% or if the patient has T2DM. Assess BMI. Add semaglutide 2.4 mg if BMI >27 kg/m² with or without diabetes per SELECT trial eligibility criteria.

For patients with triglycerides 135 to 499 mg/dL on statin therapy, add icosapent ethyl 4 g/day. For patients with recurrent MACE events on optimal therapy, colchicine 0.5 mg/day is a reasonable add-on. For patients with polyvascular disease or PAD with low bleeding risk, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day warrants discussion.

The 2021 ESC Guidelines state: "The objective of secondary prevention is to reduce the risk of recurrent events to the lowest achievable level through the combination of lifestyle changes and evidence-based pharmacological treatments" [3].